Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

4 medications associated with ↓ risk: gemfibrozil (reduction of triglycerides), ibuprofen (anti‐inflammatory), ceftriaxone (antibiotic), cholecalciferol (vitamin D3)

Source: Study characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Data‐driven discovery of associations between prescribed drugs and dementia risk: A systematic review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Data‐driven discovery of associations between prescribed drugs and dementia risk: A systematic review

Systematic review · Alzheimer's & Dementia : Translational Research & Clinical Interventions · 2025

Original publication title

Data‐driven discovery of associations between prescribed drugs and dementia risk: A systematic review

Benjamin R. Underwood; Ilianna Lourida; Jessica Gong; Stefano Tamburin; Eugene Yee Hing Tang; Emad Sidhom; Xin You Tai; Matthew J. Betts; Janice M. Ranson; Margarita Zachariou; Olajide E. Olaleye; Saswati Das; Neil P. Oxtoby; Shanquan Chen; David J. Llewellyn; for the Deep Dementia Phenotyping (DEMON) Network

© 2025 The Author(s). Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: Abstract

Recent clinical trials on slowing dementia progression have led to renewed focus on finding safer, more effective treatments. One approach to identify plausible candidates is to assess whether existing medications for other conditions may affect dementia risk. We conducted a systematic review to identify studies adopting a data‐driven approach to investigate the association between a wide range of prescribed medications and dementia risk. We included 14 studies using administrative or medical records data for more than 130 million individuals and 1 million dementia cases.

Despite inconsistencies in identifying specific drugs that may modify Alzheimer's or dementia risk, some themes emerged for drug classes with biological plausibility. Antimicrobials, vaccinations, and anti‐inflammatories were associated with reduced risk, while diabetes drugs, vitamins and supplements, and antipsychotics were associated with increased risk. We found conflicting evidence for antihypertensives and antidepressants. Drug repurposing for use in dementia is an urgent priority. Our findings offer a basis for prioritizing candidates and exploring underlying mechanisms.

Source: Abstract

Abstract: Highlights

  • ·

    We present a systematic review of studies reporting association between drugs prescribed for other conditions and risk of dementia including 139 million people and 1 million cases of dementia.

  • ·

    Our work supports some previously reported associations, for example, showing decreased risk of dementia with drugs to treat inflammatory disease and increased risk with antipsychotic treatment.

  • ·

    Antimicrobial treatment was perhaps more surprisingly associated with decreased risk, supportive of recent increased interest in this potential therapeutic avenue.

  • ·

    Our work should help prioritize drugs for entry into adaptive platform trials in Alzheimer's disease and will serve as a useful resource for those investigating drugs or classes of drugs and risk of dementia.

Source: Highlights
Authors’ abstract

Abstract

Recent clinical trials on slowing dementia progression have led to renewed focus on finding safer, more effective treatments. One approach to identify plausible candidates is to assess whether existing medications for other conditions may affect dementia risk. We conducted a systematic review to identify studies adopting a data‐driven approach to investigate the association between a wide range of prescribed medications and dementia risk. We included 14 studies using administrative or medical records data for more than 130 million individuals and 1 million dementia cases.

Despite inconsistencies in identifying specific drugs that may modify Alzheimer's or dementia risk, some themes emerged for drug classes with biological plausibility. Antimicrobials, vaccinations, and anti‐inflammatories were associated with reduced risk, while diabetes drugs, vitamins and supplements, and antipsychotics were associated with increased risk. We found conflicting evidence for antihypertensives and antidepressants. Drug repurposing for use in dementia is an urgent priority. Our findings offer a basis for prioritizing candidates and exploring underlying mechanisms.

Highlights

  • ·

    We present a systematic review of studies reporting association between drugs prescribed for other conditions and risk of dementia including 139 million people and 1 million cases of dementia.

  • ·

    Our work supports some previously reported associations, for example, showing decreased risk of dementia with drugs to treat inflammatory disease and increased risk with antipsychotic treatment.

  • ·

    Antimicrobial treatment was perhaps more surprisingly associated with decreased risk, supportive of recent increased interest in this potential therapeutic avenue.

  • ·

    Our work should help prioritize drugs for entry into adaptive platform trials in Alzheimer's disease and will serve as a useful resource for those investigating drugs or classes of drugs and risk of dementia.

Publication and source details

Original title: Data‐driven discovery of associations between prescribed drugs and dementia risk: A systematic review

Benjamin R. Underwood; Ilianna Lourida; Jessica Gong; Stefano Tamburin; Eugene Yee Hing Tang; Emad Sidhom; Xin You Tai; Matthew J. Betts; Janice M. Ranson; Margarita Zachariou; Olajide E. Olaleye; Saswati Das; Neil P. Oxtoby; Shanquan Chen; David J. Llewellyn; for the Deep Dementia Phenotyping (DEMON) Network

Alzheimer's & Dementia : Translational Research & Clinical Interventions · 2025

* Correspondence
Benjamin R Underwood, PhD, Windsor Unit, Fulbourn Hospital Cambridge CB21 5EF, UK.
Email: bru20@cam.ac.uk
© 2025 The Author(s). Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.NIHR Cambridge Biomedical Research Centre 10.13039/501100018956NIHR203312National Institute for Health and Care Research (NIHR)National Institute of AgingR01AG17644National Institute for Health and Care Research 10.13039/501100000272Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)425899994German Federal Ministry of Education and Research01ED2102BNeurodegenerative Disease ResearchNational Institute for Health Research University College London Hospitals Biomedical Research CentreNIHR Exeter Biomedical Research CentreAlan Turing Institute 10.13039/100012338Engineering and Physical Sciences Research Council 10.13039/501100000266EP/N510129/1Alzheimer's Research UKNational Institute for Health Research Applied Research Collaboration South West Peninsula 10.13039/501100019219Alan Turing Institute/Engineering and Physical Sciences Research Councilthe Early Detection of Alzheimer's Disease SubtypesUKRI Future Leaders FellowSonderforschungsbereicheDeutsche Forschungsgemeinschaft 10.13039/501100001659425899994NIHR Clinical LecturerNational Institute on Aging 10.13039/100000049R01AG17644

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T07:05:14.099237+00:00

DOI: 10.1002/trc2.70037 · PMC11747987